Fund moves
84 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 25, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jan 23, 2026 · Filed Jan 26, 2026
The CEO of Abbott Laboratories paid $2.01M out of pocket for Abbott Laboratories shares. 1 other person at Abbott Laboratories bought some too, in the same month. Shares held went up 10% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$2,013,967
Shares × reported transaction price
$1M+
+9.5%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 8.3% of the CEO's reported total pay for fiscal 2025 ($24.2M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-13. The proxy names Robert B. Ford as CEO for that year. A size comparison, not a judgement
1 day after results of Jan 22, 2026, 83 days before results of Apr 16, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $107.42 on Jan 23, 2026, at its 52-week low, after an 11% drop over the previous 30 trading days
52-week range $107.42 (Jan 23, 2026) to $140.22 (Mar 3, 2025), 0% of the way up, from 251 adjusted closes. 30 trading days earlier: $121.25 on Dec 9, 2025. Describes the past only, not a forecast
RSI 17, 17% under its 200-day average, 14% under its 50-day average, 23% below the 52-week high, 20-day volatility 39% a year, against the S&P 500: −15 points over 1 month, −19 points over 3 months, −23 points over 6 months
From the adjusted closes up to Jan 23, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any ABT insider since Feb 2021. Robert B Ford's largest purchase of ABT in their filings since 2016. Robert B Ford's first purchase of ABT since Dec 2016
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.7% | −0.9% | +1.6% |
| 30 days | +7.4% | −0.9% | +8.3% |
| 90 days | −14.3% | +2.8% | −17.1% |
| 180 days | −3.5% | +6.3% | −9.8% |
Past results only. Not a forecast.
Fund moves
84 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 25, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
83 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 20, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Congress
Traded Jan 29 · disclosed 21 days laterSits on House Energy and Commerce
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.